Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12700245 | 0.86 | KMT2A (0.72) | KMT2AMEN1HPGDPOLBENPP2 | |
| SCHEMBL25705423 | 0.86 | KMT2A (0.59) | KMT2AMEN1HPGDLMNAPOLB | |
| SCHEMBL21012277 | 0.86 | CACNA1G (0.60) | KMT2AMEN1HPGDLMNACACNA1G | |
| SCHEMBL18132362 | 0.86 | CACNA1G (0.60) | KMT2AMEN1HPGDLMNAPOLB | |
| SCHEMBL5010059 | 0.84 | KMT2A (0.68) | KMT2AMEN1HPGDPOLBCACNA1G | |
| SCHEMBL5010938 | 0.84 | KMT2A (0.72) | KMT2AMEN1HPGDPOLBCACNA1G | |
| SCHEMBL5010540 | 0.83 | KMT2A (0.64) | KMT2AMEN1HPGDPOLBENPP2 | |
| SCHEMBL18132357 | 0.82 | KMT2A (0.61) | KMT2AMEN1HPGDPOLBENPP2 | |
| SCHEMBL5010573 | 0.81 | KMT2A (1.00) | KMT2AMEN1HPGDPOLBENPP2 | |
| SCHEMBL10304923 | 0.81 | PTGS1 (0.65) | KMT2AMEN1HPGDLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319098-B2 | 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-15 | — | — | US | disclosed |
| US-20070259867-A1 | 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259867-A1 | 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL | CACNA1I, CACNA1G, CACNA1H | KMT2A 4804/4885MEN1 959/4885HPGD 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.